Observations placeholder
Revlimid
Identifier
017716
Type of Spiritual Experience
Background
A description of the experience
Lenalidomide
marketed as Revlimid is a derivative of thalidomide introduced in 2004. It was initially intended as a treatment for multiple myeloma but is also used for a group of hematological disorders known as myelodysplastic syndromes (MDS). In vitro, lenalidomide has three main activities: direct anti-tumor effect, inhibition of the microenvironment support for tumor cells, and immunomodulatory role. In vivo, lenalidomide induces tumor cell apoptosis directly and indirectly by inhibition of bone marrow stromal cell support, and by immunomodulatory activity.
Lenalidomide, like its parent compound thalidomide, may cause venous thromboembolism (VTE), a potentially serious complication with their use. Other potential side effects are thrombosis, pulmonary embolus, and hepatotoxicity, as well as bone marrow toxicity resulting in neutropenia and thrombocytopenia. The drug is being investigated for possibly increasing the risk of developing Stevens-Johnson syndrome, a life-threatening condition affecting the skin.
On Dec, 29, 2016 117,888 people reported to have side effects when taking Revlimid. Among them, 261 people (0.22%) have Hallucination
Time on Revlimid when people have Hallucination :
| < 1 month | 1 - 6 months | 6 - 12 months | 1 - 2 years | 2 - 5 years | 5 - 10 years | 10+ years | |
| Hallucination | 60.00% | 32.73% | 3.64% | 1.82% | 1.82% | 0.00% | 0.00% |
Gender of people who have Hallucination when taking Revlimid :
| Female | Male | |
| Hallucination | 40.96% | 59.04% |
Age of people who have Hallucination when taking Revlimid :
| 0-1 | 2-9 | 10-19 | 20-29 | 30-39 | 40-49 | 50-59 | 60+ | |
| Hallucination | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 1.29% | 9.68% | 89.03% |